Pancreatic Disorders News

The Pancreatic Cancer Action Network said pancreatic cancer will become the second leading cause of cancer death by 2030, according to research presented by the group’s vice president of scientific and medical affairs, Lynn Matrisian, PhD, MBA, at an American Association for Cancer Research special teleconference, Pancreatic Cancer: Innovations in Research and Treatment.

Small doses of an investigational radioimmunotherapy combined with small doses of the chemotherapy drug gemcitabine were shown to provide “superior outcomes” over radioimmunotherapy alone, according to research presented today at an American Association for Cancer Research conference, Pancreatic Cancer: Innovations in Research and Treatment.

Three new biomarkers, in addition to known biomarker CA 19-9, have been identified as an effective blood-based panel for pancreatic cancer screening at an early stage.

Simvastatin use was associated with a reduced risk of acute pancreatitis, according to new research.

Many patients with pancreatic adenocarcinoma initially presented with an episode of acute pancreatitis, and as long as 2 years elapsed between diagnoses, according to results of a retrospective study.

Patients with intraductal papillary mucinous neoplasm of the pancreas who exhibited hypoattenuated areas on computed tomography imaging were at increased risk for mortality that was lowered by surgical resection in a recent study.

Patients with pyogenic liver abscess are more than four times more likely to have gastrointestinal cancer, according to study results.

Use of covered, self-expanding metal stents that employ an anti-migration system resulted in improved patency duration without additional complications for patients with distal biliary obstruction caused by pancreatic carcinoma in a recent study.

The FDA announced it will allow marketing of the Axios Stent and Delivery System to treat fluid- and tissue-filled cavities in the pancreas and adjacent to the stomach or small intestine, according to a news release.

WASHINGTON — The competitive survival rates achieved using nontransplantation options for patients with metastatic neuroendocrine tumors of gastroentero-pancreatic origin along with the lack of accepted selection criteria has made the use of liver transplant in these cases controversial, a speaker said here.